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Introduction
Head and neck cancers are a common group of  malignancies. 
They rank sixth among the cancers, and accounting for 6% 
of  all cancer cases globally1. In early stages the disease is 
highly curable with either radiotherapy or surgery, and these 
modalities offer equivalent survival outcomes. However, 
most patients up to 60%  present with advanced disease 
which confers a poor prognosis2. The role of  chemotherapy 
in head and neck cancers has evolved over time. The first 
big meta-analysis of  chemotherapy in head and neck cancer 
(MACH-NC) involving over ten thousand patients failed to 
demonstrate benefit of  neo-adjuvant chemotherapy in head 
and neck cancers, which was only demonstrated in concurrent 
chemo-radiation. The meta-analysis was largely looking for 
survival benefit. The Veteran approach of  neo-adjuvant 
chemotherapy for laryngeal preservation was one of  the first 
trials to report a positive role of  neo-adjuvant chemotherapy 
but for laryngeal preservation other than survival benefit.3 
Later, TAX trials demonstrated that induction chemotherapy 
with Cisplatin, 5- Fluorouracil and Taxotere (TPF) regimen 
followed by concurrent chemo-radiation for patients with 
locally advanced head and neck cancer is more effective and 
tolerable4. The neo-adjuvant chemotherapy in this protocol 
demonstrated survival advantage. This is the recent standard 
of  care for locally advanced head and neck cancers in good 
performance status patients. Palliative radiotherapy forms the 
main stay of  treatment in locally advanced cases that are not 
fit for radical treatment. However, the management of  HIV 
infected locally advanced head and neck cancer is not clearly 
established. HIV infected patients tolerate chemotherapy 
poorly, are more likely to suffer severe toxicity, with higher 
possibility of  declining CD4 count, rebound in HIV viral 
load and septic complications5,6,7. Further challenges exist 
in areas where radiotherapy access is a major challenge. We 
report a case of  a locally advanced head and neck cancer of  
squamous cell histology, HIV infected who was down-staged 
using non-TPF neo-adjuvant chemotherapy in a setting 
where there is no radiotherapy and achieved near complete 
response and enabled a potentially curative resection 
procedure be performed.
Presentation
A 36 year old female patient HIV reactive on antiretroviral 
therapy (Triommune: Neverapine, Stavudine and Lamivudine 
fixed dose combination) for five years. She was referred to our 
hospital, Queen Elizabeth Hospital (QECH) at the Oncology 
Unit, with a main complaint of  progressive swelling of  the 
right cheek for 4 months. The patient reported having an 
episode of  toothache prior to this, following which she had a 
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there was no marked improvement in the swelling.
Clinical	examination
Patient weighed 47kgs, height 154.5cm, BMI 19.7kg/m2. 
Inspection revealed a left cheek tumour with a surface that 
was partially ulcerated, with pus discharging sinuses. The 
tumour was oval in shape, hard measuring 7cm X 6cm. Oral 
evaluation revealed a mass on the left cheek with ulceration 
of  the mucosal surface and no other findings. (See Figure 1 
pre-chemo). There was trismus of  about a centimetre, which 
precluded detailed oral assessment. There was no clinically 
palpable submandibular, cervical and supraclavicular 
regional lymphadenopathy. Examination of  the rest of  the 
systems were non-remarkable with no obvert stigmata of  
HIV infection.
Investigations
Incision biopsy was performed and pathological examination 
of  the submitted specimen confirmed ulcerated oral 
mucosa with an invasive poorly differentiated squamous 
cell carcinoma extending to the lateral and deep margins 
of  the biopsy. X-rays of  the affected region demonstrated 
destruction of  the left aspect of  the body of  the mandible 
sparing the angle. The base-line full blood count done 
demonstrated a leucocytosis with white cell count of  22 
and lymphocyte predominance. Haemoglobin revealed 
mild anaemia and there was mild thrombocytosis as shown 
in table 1, column of  base-line values. Her CD4 count had 
increased to 560cells/mm³ from the initial 42 cells/mm³done 
five years prior. The baseline urea, electrolytes and creatinine 
were normal, and the rest of  the blood test results generated 
during the patient’s different visits to the oncology unit is as 
shown in Table 1.
Table 1 showing blood results during different patient’s visits
Treatment
The patient received 5 days course of  Metronidazole and 
flucloxacillin to control the infection before commencing 
her on chemotherapy. 
One month after initial presentation the patient was 
commenced on chemotherapy. Prior to commencing 
chemotherapy, patient’s performance status was ECOG 
1, had reasonable haematological counts and a good renal 
clearance. She was started on Paclitaxel at 135mg/m² day 1 
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and Cisplatin calculated at 70mg/m² day 2given three-weekly 
for four cycles were administered. Prior to her second cycle 
of  treatment, the haemoglobin decreased to 8.7 and required 
transfusion of  whole blood.
Assessment post-chemotherapy (four cycles) revealed 
remarkable tumour regression. The patient had near 
complete response (see figure 1 post-chemo).
The patient was assessed jointly with oncology team and 
a plastic surgeon and excision was agreed upon. This was 
discussed with the patient who consented for the procedure.
Figure 1 shows pictures taken before and after chemotherapy
The patient underwent radical surgery in order to improve 
her survival period. Therefore 1 cm margins of  normal 
skin and bone were taken. The resulting through to 
through defect was reconstructed using a pectoralis major 
osteomyocutaneous flap containing the fifth rib to fill the 
bony defect. The rib was plated to the mandible.
Figure 2 demonstrates post-resection with the osteomyocutaneous flap
The patient had an uneventful postoperative course. The 
flap took up successfully with no ensuring defect or septic 
complication (see Figure 2).
Further	follow-up
Following successful resection the patient was being planned 
for external referral to a foreign country for radiotherapy but 
patient defaulted. The patient had a documented recurrence 
at 9 months after resection with a lesion on the cheek 3 x 3 
cm plus a sternal recurrence on the incision line following a 
this disease free duration. This time she had a super-imposed 
infection that was cleared with anti-biotics. She was assessed 
in a combined surgery-oncology review and decision was 
to re-challenge her with chemotherapy (Cisplatin-5FU) but 
patient died only after a single cycle with neutropenic sepsis.
Discussion
Majority of  the patients, close to 60% with head and neck 
cancer present with locally advanced disease which confers 
poor prognosis despite disease being highly curable in its 
early stages. This case represents one of  such cases where 
the tumour was staged as T4 due to bone involvement. 
The history of  an oral tumour being mistaken and treated 
as toothache is a commonly encountered experience in the 
developing world. This is likely to explain advanced stage 
diagnoses in some of  the cases and in our patient in particular.
To improve outcomes of  the disease, chemotherapy has 
been incorporated into a combined modality approach 
involving surgery or radiation. Induction chemotherapy with 
Cisplatin, 5- Fluorouracil and Taxotere (TPF) has become 
the standard regimen for patients with locally advanced head 
and neck cancer instead of  Cisplatin and 5-Fluorouracil 
(PF) induction. The TAX randomised trials demonstrated 
significant 2 year patients’ survival and better loco regional 
control of  disease in the group that received TPF compared 
to the group that received PF8. However, our patient was 
treated with Paclitaxel and Cisplatin but managed to achieve 
near complete response as shown in Fig 1. Paclitaxel has 
shown marked activity in head and neck cancer with a 
single agent response of  about 40%9. Concurrent induction 
chemotherapy with Paclitaxel and Cisplatin has been shown 
to achieve greater response in other series. In one prospective 
study looking at induction chemotherapy with Paclitaxel and 
Cisplatin to concurrent radiotherapy and weekly Paclitaxel 
in the treatment of  loco-regionally advanced, stage IV (M0), 
head and neck squamous cell carcinoma demonstrated 
(n=43) 32 overall tumour responses, 74.4% (23 partial and 
9 complete) after three cycles of  induction chemotherapy11. 
Assessment of  our patient after the four cycles revealed 
marked tumour regression making it operable in an initially 
inoperable tumour, suggesting that this approach may 
be investigated or employed for down-staging advanced 
tumours before surgery. This may be considered in desperate 
situations where radiotherapy is not possible, like in our 
setting to allow surgery in properly selected patients. This 
regimen however has significant toxicity hematological and 
non-hematological. Our patient had anaemia prior to her 
second cycle requiring transfusion of  one unit of  packed red 
cells but did not develop any alopecia, mucosal, neurological, 
nephrotoxic, or neutropenic complications. Our patient 
tolerated this protocol reasonably well.
Management of  HIV infected patients with locally advanced 
head and neck cancers pose a challenge due to lack of  
evidence on how such patients ought to be treated. AIDS 
related immunodeficiency is well established risk factor 
for development of  cancer and also present a unique 
challenge in patient’s ability to tolerate cancer therapy.2,5,12 
The introduction of  highly active antiretroviral therapy 
(HAART), allows most patients live with either mild or 
moderate degrees of  immunodeficiency. In our case, the 
patient had been on HAART for five years and had a very 
good immunologic response with CD count of  560 cells/
mm3 at the time of  chemotherapy commencement. On 
completion of  the four cycles of  chemotherapy, the patient 
achieved significant tumour reduction to near complete 
response as seen on post-chemotherapy in figure 1 post-
chemotherapy pictures. The patient still remained immuno-
competent and fit to under-go surgery.
This case suggests that it is possible to down stage a locally 
advanced head and neck cancer using Paclitaxel-Cisplatin 
regimen in an HIV positive patient and convert such a stage 
to a resectable state. Though a combination of  HIV infection 
and locally advanced cancer posed a big challenge in our 
case due to an irresistible tumour and lack of  radiotherapy, 
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chemotherapy offered an opportunity to shrink the tumour 
mass remarkably hence offering this patient a possibility of  
a potentially curative surgical resection. In situations where 
the patient may not be operated, this may still offer excellent 
palliation by elimination of  mass effect, pain, discharging 
sinuses and bleeding. This will at the same time improve 
quality of  life.
The therapy offered though did not eventually cure this 
patient, it still offered a good quality of  life for a year. The 
proposed post-operative radiotherapy in this patient could 
have prevented the recurrence and prolonged the survival 
period. 
This case suggests benefit of  neoadjuvant chemotherapy in 
head and neck cancer in HIV infected individuals.
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